68Ga-NOTA-WL12肽类PET显像剂在非小细胞肺癌患者的首次人体研究
本研究对9例晚期非小细胞肺癌患者进行了68Ga-NOTA-WL12的首次人体PET显像,评估其生物分布、代谢、辐射剂量学、安全性及定量PD-L1表达的能力。结果显示该显像剂安全、辐射剂量学可接受,肿瘤摄取与PD-L1免疫组化结果强正相关(r=0.9349;P=0.002),且治疗前PD-L1 PET可能提示帕博利珠单抗联合化疗的疗效。
要点
- 68Ga-NOTA-WL12 PET显像安全,辐射剂量学可接受,主要生理性摄取见于肝、脾、小肠和肾。
- 肿瘤摄取(SUVpeak)与PD-L1免疫组化结果强正相关(r=0.9349;P=0.002)。
- 治疗前PD-L1 PET可能提示帕博利珠单抗联合化疗的疗效。
核心结论
- 首次人体研究结果表明68Ga-NOTA-WL12安全可行,可无创在体内检测肿瘤PD-L1表达水平,可能对临床PD-L1治疗有益。
研究设计与样本
- 研究纳入9例表达PD-L1的晚期非小细胞肺癌患者,进行68Ga-NOTA-WL12与配对18F-FDG PET/CT显像,监测不良事件并评估生物分布、辐射剂量学及肿瘤摄取与PD-L1表达的关系。
主要发现
- 68Ga-NOTA-WL12在体外和PD-L1阳性荷瘤小鼠体内显示PD-L1特异性摄取。
- 68Ga-NOTA-WL12 PET显像安全,辐射剂量学可接受;主要生理性摄取见于肝、脾、小肠和肾,肿瘤在肺部清晰可见,1小时肿瘤与肺比值(T/L)为4.45±1.89。
- 1小时是合适的图像采集时间点,因为1小时与2小时之间的肿瘤与本底比值无显著差异。
- 肿瘤摄取(SUVpeak)与PD-L1免疫组化结果呈强正相关(r=0.9349;P=0.002)。
- 68Ga-NOTA-WL12与18F-FDG PET研究提示,治疗前PD-L1 PET可能预示帕博利珠单抗联合化疗的疗效。
临床怎么用
- 68Ga-NOTA-WL12 PET可用于无创评估肿瘤PD-L1表达水平,治疗前显像可能辅助预测帕博利珠单抗联合化疗的疗效。
局限性
- 本研究为首次人体研究,样本量仅9例,结论需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
68Ga-NOTA-WL12 is a peptide-based PET imaging agent. We conducted a first-in-human study of 68Ga-NOTA-WL12 for PET to study the in vivo biodistribution, metabolism, radiation dosimetry, safety, and potential for quantifying programmed death ligand-1 (PD-L1) expression levels in patients with advanced non-small cell lung cancer (NSCLC). Methods: In vitro assessment of the PD-L1 expression and cellular uptake of 68Ga-NOTA-WL12 was performed, followed by in vivo evaluation of 68Ga-NOTA-WL12 uptake in mouse models with tumors. Nine patients with NSCLC with lesions expressing PD-L1 were enrolled and monitored for adverse events during the study. 68Ga-NOTA-WL12 and paired 18F-FDG PET/CT imaging were performed. Uptake (SUV, SUL [SUVlean], and kBq/mL) values of tumors and normal organs were obtained. Radiopharmaceutical biodistribution, radiation dosimetry, and the relationship of tumor uptake to PD-L1 expression were evaluated. Follow-up 18F-FDG PET/CT was performed in patients who had undergone treatment with a combination of pembrolizumab with chemotherapy. Results:68Ga-NOTA-WL12 exhibited PD-L1-specific uptake in vitro and in PD-L1-positive tumors in vivo. 68Ga-NOTA-WL12 PET imaging proved safe with acceptable radiation dosimetry. Physiologic tracer uptake was mainly visible in the liver, spleen, small intestine, and kidney. Tumors were clearly visible, particularly in the lungs, with a tumor-to-lung ratio of 4.45 ± 1.89 at 1 h. One hour was a suitable time point for image acquisition because no significant differences were noted in tumor-to-background ratios between 1 and 2 h. A strong, positive correlation was found between tumor uptake (SUVpeak) and PD-L1 immunohistochemistry results (r = 0.9349; P = 0.002). 68Ga-NOTA-WL12 and 18F-FDG PET studies suggest that PD-L1 PET before therapy may indicate the therapeutic efficacy of pembrolizumab plus chemotherapy combination treatment. Conclusion: Our first-in-human findings demonstrate the safety and feasibility of 68Ga-NOTA-WL12 for noninvasive, in vivo detection of tumor PD-L1 expression levels, indicating potential benefits for clinical PD-L1 therapy.
引用
- Zhou X, Jiang J, Yang X, et al. First-in-Humans Evaluation of a PD-L1-Binding Peptide PET Radiotracer in Non-Small Cell Lung Cancer Patients. J Nucl Med. 2021. PMID: 34326125. doi:10.2967/jnumed.121.262045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。